Results for this period
Full year1 October 2025–30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue increased due to growth in the number of cell-processing cases, expansion of partner medical institutions, and technology-transfer- and setup-related revenue from the CDMO business. Gross profit increased due to a partial review of the expense allocation method and lower cost of sales, while selling, general and administrative expenses increased due to higher research and development expenses, resulting in a wider operating loss. An ordinary loss was recorded due to gains on investment business partnerships and other factors, while a net loss was recorded due to valuation losses on investment securities and other factors.
There is a description of significant events and other matters. Although the Company determined that risks exist due to continuing operating losses and negative operating cash flow, it concluded that no material uncertainty was identified. No note regarding the going concern assumption was applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 October 2025–30 September 2026 |
| Net Sales | 821 Millions of yen (YoY +1.4%) |
| Operating profit | -1,520 Millions of yen |
| Ordinary income | -1,360 Millions of yen |
| Profit attributable to owners of the parent | -1,397 Millions of yen |
| Net income per share | ¥(5.09) |
| Operating Margin | -185 % |
| Equity ratio | End of the current fiscal period 81 / End of previous period 88.8 |
| Total assets | 3,580 Millions of yen |
| Net assets | 2,908 Millions of yen |
| Cash flows from operating activities | -1,332 Millions of yen |
| Cash flows from investing activities | 553 Millions of yen |
| Cash flows from financing activities | 532 Millions of yen |
| Cash and cash equivalents at end of period | 2,423 Millions of yen |
| Full-year earnings forecast | Net Sales 992 Millions of yen (YoY +20.7%) / Operating profit -1,154 Millions of yen / Ordinary income -1,154 Millions of yen / Net income -1,206 Millions of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen |
| Segment revenue | Cell-processing business 821,417 Thousands of yen (YoY +1.4%) / Regenerative medicine products business 316 Thousands of yen (YoY +44.3%) |
| Segment profit | Cell-processing business -420,447 Thousands of yen / Regenerative medicine products business -564,540 Thousands of yen |
| Depreciation and amortization | 101 Millions of yen |
| Impairment loss | None recorded for the period (no impairment losses were applicable to any reportable segment) |
| Breakdown of extraordinary income (loss) | Extraordinary income None / Extraordinary loss Item Loss on disposal of fixed assets / Amount 1,390 Thousands of yen, Item Loss on valuation of investment securities / Amount 33,160 Thousands of yen |
| Disclosure regarding the going concern assumption | There is a description of significant events and other matters. Although the Company determined that risks exist due to continuing operating losses and negative operating cash flow, it concluded that no material uncertainty was identified. No note regarding the going concern assumption was applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | At a Board of Directors meeting held on 30 October 2026, the Company resolved to implement business structure reforms aimed at strengthening its management base. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Held (for institutional investors and analysts) |
| Issued Shares at Period-End | 284,667,319 shares |
| Treasury Shares at Period-End | 162 shares |
| Factors Behind Changes in Business Performance | Revenue increased due to growth in the number of cell-processing cases, expansion of partner medical institutions, and technology-transfer- and setup-related revenue from the CDMO business. Gross profit increased due to a partial review of the expense allocation method and lower cost of sales, while selling, general and administrative expenses increased due to higher research and development expenses, resulting in a wider operating loss. An ordinary loss was recorded due to gains on investment business partnerships and other factors, while a net loss was recorded due to valuation losses on investment securities and other factors. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue and gross profit increased due to growth in the number of cell-processing cases and technology-transfer-related revenue from the CDMO business. However, selling, general and administrative expenses increased due to higher research and development expenses, resulting in a wider operating loss.